Category: Include on Menu

Crude prices slipped on Thursday, giving back part of Wednesday’s rally as traders assessed the implications of a U.S. seizure of a sanctioned Venezuelan tanker and evaluated the latest projections from the International Energy Agency. By 08:00 ET (13:00 GMT), February Brent futures were down 1.1% at $61.53 a barrel, while West Texas Intermediate crude…

Eli Lilly (NYSE:LLY) climbed 3% in premarket trading Thursday after unveiling landmark Phase 3 data for its experimental triple-agonist therapy, retatrutide, showing extraordinary levels of weight reduction alongside major improvements in osteoarthritis symptoms. In the TRIUMPH-4 study, individuals with obesity and knee osteoarthritis who received the highest 12 mg dose lost an average of 28.7%…

AC Immune (NASDAQ:ACIU) surged 25% on Thursday after announcing promising interim Phase 2 findings for its experimental Parkinson’s disease treatment, indicating the therapy may help slow the underlying progression of the disorder. The company’s investigational therapy, ACI-7104.056 — an active immunotherapy targeting alpha-synuclein — produced encouraging outcomes in the VacSYn study involving patients in the…

Geron Corporation (NASDAQ:GERN) said Thursday it will carry out a major restructuring effort that includes reducing its workforce by around one-third — a move that will impact roughly 260 employees at the biopharmaceutical firm. The overhaul is expected to be largely completed during the first quarter of 2026. Geron anticipates that its operating expenses for…

zSpace Inc. (NASDAQ:ZSPC) announced Thursday that it has wrapped up a major restructuring initiative that included substantial workforce reductions and operational adjustments across its U.S. business. The augmented reality education technology company said the changes will lower its run-rate operating expenses by more than 30%. The overhaul included what the company described as significant staff…

Rezolute, Inc. (NASDAQ:RZLT) saw its stock plunge 90% on Thursday after revealing that its Phase 3 sunRIZE trial of ersodetug in congenital hyperinsulinism (HI) patients failed to achieve its primary endpoint or its key secondary objectives. According to the company, the study recorded roughly a 45% reduction in hypoglycemia events at the highest dose tested…

Coherent Corp. (NYSE:COHR) dropped 1.8% on Thursday after Bain Capital put forward another sizable share sale, marking the private equity firm’s third attempt in just over a month to trim its position in the laser systems manufacturer. According to Bloomberg News, citing sources familiar with the deal, Goldman Sachs Group Inc. (NYSE:GS) is marketing 5…

Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP) climbed 5% after the company released promising early-stage safety data for CRB-913, its oral CB1 inverse agonist under development for obesity treatment. The Phase 1a trial showed that CRB-913 was well tolerated, with no serious adverse events reported across both single- and multiple-ascending-dose cohorts. Importantly, the study revealed early signs…